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ABSTRACT 
The epoxymethano analogs of PGH2 caused rapid and persistent 
increase in perfusion pressure in isolated rat pancreata without 
significant effect on glucagon and insulin secretory responses 
to PGH2 and PGE2. The changes in perfusion pressure are inter- 
preted as alterations in vascular resistance since the flow rate 
was kept constant at 2.5 mL per min. PGH2 alone caused signifi- 
cant elevation in pressure. However, PGH2 administration super- 
imposed upon an infused epoxymethano analog of PGH2, decreased 
perfusion pressure significantly, whereas PGH2 induced hormone 
release was not decreased. The analogs neither stimulated nor 
inhibited the endocrine pancreas secretion. These studies pro- 
vide evidence for complete dissociation of vascular constriction 
from pancreatic hormone release and further suggest that the ef- 
fects of PGH2 on islet hormone secretion may result from the 
conversion of PGH2 to other prostanoids. 
INTRODUCTION 
Previous reports (1,2,3,4) demonstrate that the synthetic analogs 
of endoperoxide, 9,11- and 11,9-(epoxymethano)-azoprosta-5,13- 
dienoic acid are stable analogs of prostaglandin H2 (lj-hydroxy- 
9,11-peroxidoprosta-5,13_dienoic acid). The epoxymethano analogs 
of PGH2 have been shown to inhibit the endoperoxide synthase and 
thromboxane synthase activity (3,4). The endoperoxide analogs 
are receptor level antagonists of both platelet aggregation and 
cyclic AMP lowering actions of PGH2 (4,5). 
Injection of 9-epoxy-11-methano into canine superior mesenteric 
artery caused dose dependent vasoconstriction and decrease in 
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blood flow. However, PGH2 injected similarly, resulted in vaso- 
dilation and increase in blood flow (6). Many prostaglandins 
exert potent pressor effects on the endocrine pancreas (7,8). 
The mechanism by which some prostaglandins inhibit the endocrine 
pancreas secretion has been attributed in part to local vasocon- 
striction (7,8). In these studies, we have observed that ll- 
epoxy-9-methano analog which exerts potent vasoconstriction on 
pancreatic vasculature, neither stimulates nor inhibits secretion 
nor antagonizes insulin and glucagon secretion in response to 
PGH2 and PGE2. 
MATERIALS AND METHODS 
Pancreata were obtained from young adult male albino rats, weigh- 
ing from 250-300 g, that were fasted for 18-24 h. The animals 
were anesthetized with sodium pentobarbital (50 mg/kg) injected 
intraperitoneally and the pancreas with its intact vasculature 
was removed and transferred to an extracorporeal perfusion appa- 
ratus, as described previously (9) and perfused with Krebs- 
Ringer-bicarbonate buffer containing 30 uM albumin, 56 UM dextran 
and 5.6 mM D-glucose, with or without epoxymethano analogs of 
PGH2. 
PGH2 was generated enzymatically from arachidonate as described 
previously (10) and was stored frozen. 11-epoxy-9-methano and 
9-epoxy-11-methano analogs of endoperoxide PGH2 and PGE2 were 
donated by Dr. John Pike of the Upjohn Company, Kalamazoo, MI. 
On the day of use, the epoxymethano analogs were dissolved in 
95% ethanol and then diluted with perfusion buffer to the desired 
concentration. PGH2 and PGE2 were dissolved in 95% ethanol and 
then diluted with perfusion buffer five seconds before use. The 
final concentration of ethanol in the perfusate was less than 
0.95%. We have shown previously that at this concentration 
ethanol does not affect secretion of glucagon or insulin (9,10, 
11). 
The perfusion flow rate was maintained constant at 2.5 mL per 
min. Perfusion pressure was monitored continuously using a pres- 
sure transducer, an amplifier and a strip-chart recorder set 
either at 0.2 in (or at 2 in per min during injection of PGH2). 
PGH2 and PGE2 were administered as a 250 UL bolus over 5-8 sec- 
onds through a diaphram in the influent line without interrupting 
the flow of the basic perfusion solution. PGH2 injections were 
made before, during and after perfusing the pancreata with buffer 
solution containing 1 uM epoxymethano analogs. The pancreatic 
portal venous effluent was collected in one-minute fractions: the 
samples were chilled immediately and aliquoted for radioimmuno- 
assays. Radioimmunoassays for glucagon and insulin were per- 
formed using a "double-antibody" method described previously (12). 
Statistical significance of differences between observed values 




The pancreas was perfused firstly, for 20 minutes with basic buf- 
fer solution containing 5.6 mM glucose (described in MATERIALS 
AND METHODS) without the endoperoxide analogs. The influent per- 
fusate was then switched to a solution containing 1 uM ll-epoxy- 
9-methano analog of PGH2 and perfusion was continued further for 
60 minutes. The influent perfusate was lastly switched again to 
the basic buffer solution. PGH2 or PGE2 was injected as a 250 UL 
bolus into the pancreas before, during and after perfusing the 
pancreata with solution containing the endoperoxide analogs. 
r 
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Fig. 1. PGH2 and endoperoxide analog induced changes in per- 
fusion pressure. Flow rate was maintained constant 
at 2.5 mL/min. Recording speed was set at 0.2 in/min 
(or increased to 2 in/min during injection of PGH2 
only). PGH2 was injected at various intervals before, 
during and after perfusion with the analog. Pressure 
values are in millimeter of mercury. 
In Figure 1 is shown qualitative perfusion pressure recordings 
obtained during one of the experiments. 11-epoxy-9-methano alone 
or +epoxy-11-methano (data not shown) caused rapid and persist- 
ent increase in the perfusion pressure. PGH2 (10 uM) alone in- 
jected before the endoperoxide analog, also exerted significant, 
although lesser increase in pressure (Figure 1, left panel). 
PGH2 (1 uM or 10 uM) injections superimposed upon influent endo- 
peroxide analog, decreased significantly the high perfusion 
pressure caused by the analog (Figure 1, middle panel). When the 
influent perfusate was switched off the analog and the pancreas 
was perfused with basic buffer solution, perfusion pressure grad- 
ually returned almost to baseline in five minutes. PGH2 again 
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increased the perfusion pressure (Figure 1, right 
changes in pressure observed in these studies are 
alterations in vascular resistance since the flow 
tained constant at 2.5 mL per minute. 
11 EPOXY-9tlETHANO (1PM 1 
panel). The 
interpreted as 
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Fig. 2. Glucagon and insulin secretion during perfusion 
of pancreas with PGH2 and endoperoxide analog. 
Hormone values are mean + SEM for 5 observations. 
Figure 2 illustrates levels of glucagon and insulin secretion 
corresponding to PGH2 injections described above and illustrated 
in Figure 1. The levels of glucagon (solid circle) and insulin 
(open circle) secretion induced by PGH2 (1 or 10 uM) before, dur- 
ing and after perfusing the pancreata with endoperoxide analog 
were not significantly different (PCO.10). The release of glu- 
cagon occurred more rapidly than that of insulin but the magni- 
tude of the responses in both hormones were similar. Endoper- 
oxide analog alone did not induce 
(Figure 1 and Table 1). Arginine ? 
lucagon or insulin secretion 
10 mM) administered to the 
pancreas at the end of the perfusion caused a significant in- 
crease in the levels of both hormones. This indicates that the 
isolated perfused pancreas was still capable of normal secretory 
response to a common secretagogue. 
In Table 1 are shown values of glucagon and insulin secreted in 
response to either PGH2, the endoperoxide analog or PGE2; and 
the corresponding quantitative changes in perfusion pressure. 





































































































































































































































































































































































































































































































































































































































and persistent elevation in pressure (90% increase above base- 
line, last column) without significant effect on hormone release 
(170+30 vs 163+17, glucagon and 140+40 vs 18Ot50, insulin). In- 
creases in glucagon and insulin levels occurred consistently in 
response to PGH2 and PGE2 (10 uM) before, during and after per- 
fusing the pancreata with the analog. Although hormone secretion 
was not significantly altered by the analog during concurrent 
perfusion of the analog with two concentrations of PGH2 (1 and 
10 uM), the perfusion pressure decreased significantly 20+2$ and 
30+3% respectively) below the observed pressure increase caused 
by the analog alone. Changes in pressure due to PGE2 (10 uM) 
were inconsistent and variable. The levels of hormone release 
and changes in pressure (PGH2 only) induced by either PGH2 or 
PGE2 after 60 minutes exposure of pancreas to the analog, were 
comparable to those obtained prior to perfusion with the analog 
(Table 1). 
DISCUSSION 
This investigation was carried out to determine the relationship 
between prostaglandin-induced changes in vascular resistance and 
endocrine pancreas secretion in the perfused pancreas. The re- 
sults demonstrate that there is no direct association between 
perfusion pressure in the pancreas and portal venous glucagon and 
insulin secretion (Figures 1 and 2). Although PGH2 decreased 
high perfusion pressure caused by ll-epoxy-9-methano analog of 
PGH2, hormone secretion induced by PGH2 was not significantly 
affected (Figures 1 and 2). Since the perfusion flow rate was 
maintained constant at 2.5 mL per minute, the observed changes in 
perfusion pressure shown in Figure 1 and in Table 1 are inter- 
preted as alterations in vascular resistance. 
The data presented in these studies dissociate local pressor and 
depressor action of prostaglandins from modulation of hormone 
release, and are in agreement with those of Saunders and Moser 
(7) who reported that the amount of insulin release by perfused 
pancreas was unaffected by PGF2a-induced vasoconstriction. 
Mandelbaum and Morgan (13) manipulated canine extracorporeal 
circulation both mechanically and by use of vasoactive agents 
in vivo and reported no change in rate of insulin secretion de- 
spiteelevated pancreatic blood flow. Growth hormone infusion 
and mechanical constriction of the inferior pancreatic artery 
diminished blood flow without proportionate decrease in insulin 
output in partially depancreatized dogs (14). However, largely 
because kallikrein, bradykinin and histamine increase capillary 
circulation, stimulate the basal- and the glucagon-induced insu- 
lin secretion in the dog (15), a direct relationship between se- 
cretion and alterqtion in microvasotone of endocrine pancreas has 
been suggested (15,16). Data shown in Table 1 are in disagree- 
ment not only with the concept of direct correlation between 
changes in vascular tone and insulin release, but provide further 
evidence (for the first time to the authors' knowledge) to disso- 
ciate prostaglandin-induced glucagon secretion from alteration 
in vascular resistance. We had reported previously that the 
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perfusion of isolated rat pancreas over 1 to 10 min period with 
:Et# 
PGE2 or PGF2u augmented the release of glucagon and insulin 
and also that PGH2 is a potent secretagogue for both pan- 
creak hormones (10). 
The mechanism of pressor and secretagogue effects of prostaglan- 
dins appears to be specific and separate. The attenuation of 
the endoperoxide analog-induced high perfusion pressure by PGH2 
(Figure 1 and Table 1) could indicate an action on the same re- 
ceptor by PGH2 and the analog as previously reported (1,4,5). 
PGH2 could have a higher affinity for the receptor but lower 
pressor activity than the analog. Therefore, concurrent adminis- 
tration of the two results in displacement of the analog by PGH2. 
However, since the perfusion of pancreas with the analog did not 
enhance hormone release, it is possible that separate prostaglan- 
din receptors exist for regulation of vasotone and modulation of 
secretion in endocrine pancreas. The secretagogue effect of PGH2 
could also be due to further conversion to other prostanoids. 
Robertson (17) has reported inhibition by intravenous infusion of 
PGEl of insulin release independent of alterations in vascular 
resistance or stimulation of the alpha-adrenergic receptors. 
The mechanism by which prostaglandins modulate the secretory ac- 
tivity of endocrine glands is often attributed to interaction of 
their specific receptors with adenylate cyclase (18), since pro- 
staglandins generally elevate levels of the nucleotide in tissues 
and affect metabolic functions regulated by cyclic AMP. The 
stimulant effect of prostaglandins endoperoxide on endocrine 
pancreas secretion could involve alteration in intracellular 
calcium concentrations although Hertelendy et al. (19) have re- 
ported that the prostaglandins are not acting as ionophores. 
Mishima and Kuriyama (20) reported depolarization of guinea pig 
stomach longitudinal muscle membrane by PGE1, PGE2 or PGF2u 
suggesting that these prostaglandins may increase calcium influx 
by stimulating electrical activity of the membrane. Change in 
membrane depolarization with the associated calcium influx in 
response to pancreatic endocrine hormone secretagogues is a well- 
established phenomenon. 
We have provided evidence that the epoxymethano analog of PGH2 
exerts rapid and potent effect on vascular tone in perfused pan- 
creas without significant effect on hormone release in response 
to PGH2 and PGE2. It is concluded that nonpathologic changes in 
microvasotone in the pancreas do not significantly alter secre- 
tory activity of the endocrine pancreas. 
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